Psoriasis is a chronic inflammatory skin disorder associated with immune dysfunction and vascular abnormalities; however, current biological therapies face challenges regarding non-response or side effects, and the precise molecular mechanisms and active ingredients by which Yinxie Granules exerts its anti-psoriatic effects remain unclear.

Here, we elucidate the therapeutic efficacy of Yinxie Granules in patient samples, IMQ-induced psoriatic mice, zebrafish, and in vitro models. We demonstrate that it ameliorates skin lesions and vascular dysfunction by specifically inhibiting the STING-NF-κB pathway during disease progression, reducing pro-inflammatory cytokines (IL-6, IFN-β), and restoring endothelial barrier integrity. Integrated with multi-omics, molecular docking, and molecular interaction assays (DARTS/CETSA), we further identify quercetin and kaempferol as the primary active constituents responsible for these effects, which directly target and bind to the STING protein to suppress downstream signaling.

This work provides a comprehensive theoretical foundation elucidating the dynamic role of the STING-NF-κB axis in psoriasis pathogenesis and clarifies the active substance basis of Yinxie Granules for dual targeting of inflammation and vasculopathy. The work entitled “Dual targeting of cutaneous inflammation and vasculopathy via STING-NF-κB blockade underlies the anti-psoriatic efficacy of Yinxie Granules” was published on Chinese Journal of Natural Medicines (published on July 20, 2026).
DOI: 10.1016/S1875-5364(26)61112-0